RedHill planning NDA for H. pylori antibiotic following second Phase III readout

By Brian Moy | Dec 7, 2018 | 1:07 AM GMT

RedHill Biopharma Ltd. (Tel Aviv:RDHL; NASDAQ:RDHL) said on Dec. 3 that it plans to submit an NDA to FDA next half for Talicia (RHB-105) as first-line treatment of Helicobacter

Read the full 295 word article

How to gain access

Continue reading with a
two-week free trial.